Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to define th Maximum Tolerated Dose (MTD) and the recommended dose (RD) of ZD6474 in combination with a fixed standard dose of gemcitabine and capecitabine

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Confirmed diagnosis of locally advanced unresectable or metastatic pancreatic adenocarcinoma

• ECOG performance status <1

• Measurable disease

Exclusion Criteria:

• Severe or uncontrolled systemic disease

• Clinically significant cardiac event such as myocardial infarction

• Any concomitant medication that may cause OTc prolongation, include Torsades de Pointes